Management

The UNION team and advisors account for more than 10 drug approvals.

 

Dr. Rasmus Toft-Kehler, Chief Executive Officer

Rasmus Toft-Kehler is the co-founder and board member of multiple biotech companies in the fields of microbiome research, immunology, and antibiotic resistance. Prior to entering biotech, Rasmus worked in leading investment banks and in management consulting, and as a board member of a family-owned enterprise that was sold in 2005.

Rasmus is the inventor of 5+ patents and has published research in leading entrepreneurship and scientific journals such as Journal of Business Venturing and Nature Reviews Microbiology.

Rasmus holds a Ph.D. in entrepreneurship from Copenhagen Business School with research stays at New York University and University of Cambridge as well as Harvard Business School.

In 2007, Rasmus led a team of four inexperienced sailors to successfully cross the Pacific Ocean.

 

Dr. Morten Sommer, Chief Scientific Officer

Morten Sommer is the co-founder of several biotech companies working within fields of drug development, industrial biotechnology and microbiome research.

Morten is also a Professor and Scientific Director at the Technical University of Denmark with a lab of 20+ Ph.Ds and Post-Doctorial researchers working primarily in the field of antibiotic resistance and the human microbiome. Morten is the inventor on 20+ issued patents, patent applications and author of scientific papers in journals such as Science, Cell and Nature and was named Top 10 under 40 on Genetic Engineering and Biotechnology News list of Biopharma Research and Business executives.

Morten holds a M.Sc. in Physics from University of Copenhagen and a Ph.D. in Biophysics from Harvard University from the laboratory of Professor George Church.

 

Dr. Philippe Andres, Chief Medical Officer

Philippe Andres is a French national with over 20 years of experience as dermatologist in the pharma industry, most recently as a member of the executive team at Galderma/Nestlé Skin Health. He has a wealth of experience in encompassing early and late stage developments, scientific communication and medical affairs.

During his career, Philippe has been involved in multiple approved products, including topicals calcitriol (Vectical®) and adapalene (Differin®), submitted more than 100 patents and has published numerous scientific papers.

Philippe is an M.D. and Board Certified Dermatologist from Nantes University, France.

 

Morten Boesen, Chief Financial Officer

Since 2011 he has worked with EQT, the largest private equity fund in the Nordics, first as an investment manager and subsequently as an executive director in EQT-owned retail company Flying Tiger Copenhagen, where he held responsibility for strategy, business development as well as global commercial and supply chain operations. Prior to that, Mr. Boesen worked as a management consultant with McKinsey & Company, in the M&A advisory of Nordea Bank and in the finance department of Novozymes, the world leader in industrial biotech.

Morten holds a M.Sc. in Finance and Accounting from Copenhagen Business School, including studies at New York University’s Stern School of Business and Tsinghua University’s School of Economics and Management.

 

Dr. Umar Hayat, VP of CMC and Supply Chain

Umar Hayat, PhD. has more than 18 years of experience in pharmaceutical development, manufacturing and supply chain. He held senior level positions with Relypsa (acquired by Galenica for 1.5B US$), Anacor (acquired by Pfizer for 5.2B US$) and Transcept Pharmaceuticals (merged with Paratek). He played a pivotal role in the CMC development and commercialization of Veltassa® (USA and EU), a treatment for hyperkalemia, Intermezzo® for MOTN insomnia, Kerydin® for onychomycosis, and Eucrisa® for atopic dermatitis.

Umar received his Ph.D. in process engineering from INP-Toulouse, France and Post-Doctoral Fellowship from Ecole Polytechnique de Montreal, Canada.

 

Dr. Lutz Wevelsiep, VP of Regulatory Affairs

Lutz Wevelsiep, Ph.D. is the Vice President of Regulatory Affairs at UNION and has more than 25 years’ experience in international Regulatory Affairs across Europe and the US within multinational and start-up companies. His experience includes EU decentralized and centralized procedures, product development from Phase I through to marketing authorization as well as particular expertise in anti-infectives. He has prepared and managed various health authority interactions with FDA, EMA and EU national agencies.

Lutz has spent 16 years as Head of Global Regulatory Affairs at Basilea Pharmaceutica. His track record includes successful completion of the European marketing authorization applications for Isavuconazole (Cresmba®), Ceftobiprole (Zevtera®) and Alitretinoin (Toctino®).

Lutz holds a Ph.D. and Postdoc in chemistry from the Max-Planck Institute in Germany.

 

Mads Jellingsø, VP of Business Development and AD Program Director

Mads Jellingsø has broad Market Access experience from Novo Nordisk A/S where he was part of building new functions for Real World Evidence generation and for Innovative Contracting. In these teams Mads was driving Novo Nordisk’s global efforts to initiate partnerships with payers and providers around evidence generation and developing new financial and outcomes-based approaches to secure access for products in hemophilia, diabetes and obesity. Prior to specializing in Market Access, Mads has worked with off-shoring and legal affairs in Novo Nordisk and also has experience from management consulting (McKinsey & Company) and banking (Nordea Markets).

Mads holds a M.Sc. in Economics from University of Copenhagen.

 

Dr. Sune Klamer Jørgensen, Director of R&D Strategy and Program Director

Sune Klamer Jørgensen has experience within R&D strategy, portfolio management and business support from Novo Nordisk A/S. He was involved in formulating research strategies, responsible for providing overviews of the progression and composition of the early research project pipeline for the governing Research Board, as well as for assisting the SVP of Global Research in developing 10-year Business Plans. Prior to Novo Nordisk, Sune worked as a management consultant in McKinsey & Co.

Sune holds a M.Sc. in Nanotechnology from University of Copenhagen and a Ph.D. in Nanotechnology and Synthetic Biology from University of Copenhagen.